Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

C-W Wu[2,4], Y-Y Lin[1], G-D Chen[1], C-W Chi[3,4], DP Carbone[5] and J-Y Chen[1,4]

[1]Institute of Biomedical Sciences, Academia Sinica, No. 128, Section 2, Yen-Chiu-Yuan Road, Taipei 11529, Taiwan, Republic of China; Departments of [2]Surgery and [3]Medical Research, Veterans General Hospital-Taipei; [4]National Yang-Ming University; Taiwan, Republic of China; [5]Division of Medical Oncology, Vanderbilt Cancer Center, University of Vanderbilt, Nashville, TN 37232-6838, USA

Summary Mutation of the *p53* tumour suppressor gene often leads to the accumulation of mutant p53 protein in tumour cells. Many cancer patients develop antibodies that recognize the overexpressed p53 protein. The presence of these antibodies is, in some tumour types, associated with poor prognosis. Gastric cancer is a highly prevalent disease associated with a high rate of mortality, there is a need for improved clinical and biological markers for disease behaviour. To investigate the clinical relevance of serum anti-p53 antibodies in patients with gastric adenocarcinoma, we have examined the sera of 501 gastric cancer patients for the presence of serum antibodies against the p53 protein. By immunoblotting analysis using a cell lysate containing overexpressed p53 protein as well as affinity-purified recombinant p53 protein as antigens, we have detected anti-p53 antibodies in 11.2% (61 of 501) of gastric cancer patients, but in none of 46 cancer-free individuals. The presence of anti-p53 antibodies was tightly associated with tumours of higher nuclear grade and lymph node metastasis, and a negative association was found between the presence of anti-p53 antibodies and survival. These results suggest that a preoperative test of serum anti-p53 antibodies in gastric cancer patients can be useful to identify subset of patients who may need gastrectomy with lymph node dissection and post-operative adjuvant therapy.

Keywords: gastric adenocarcinoma; serum anti-p53 antibodies; lymph node metastasis; nuclear grade; poor prognosis

Alterations of tumour suppressor gene *p53* is the most commonly observed genetic lesion in human cancers (Levine et al, 1991). *p53* alterations have a profound impact on tumour biology and the outcome of patients with many different tumour types. Most *p53* gene alterations are mis-sense mutations, and most of those lead to the synthesis of a mutant protein with a longer than normal half-life (Lane and Benchimol, 1990; Davidoff et al, 1991), and thus massive overexpression of the protein product. In many cases, this accumulated mutant p53 protein can induce a specific humoral response in patients with various types of cancer (Crawford et al, 1982; Caron de Fromentel et al, 1987; Winter et al, 1992; Lubin et al, 1993, 1995; Angelopoulou et al, 1994).

In general, anti-p53 antibodies have been found in cancer patients whose tumours contained p53 mis-sense mutations, but not in cancer-free populations, or in patients whose tumour had p53 splice/stop, splice, or frameshift mutations (Winter et al, 1992; Wild et al, 1995). These antibodies recognize both the wild-type and mutant p53 conformational and denaturation-resistant epitopes (Davidoff et al, 1992; Schlichtholz et al, 1992). Furthermore, naturally arising anti-p53 antibodies have been

shown to recognize immunodominant epitopes in the carboxyl- and amino-terminal domains of the p53 polypeptide and these locations do not correspond to mutational hot-spots (Lubin et al, 1993; Wild et al, 1995). Although p53 immune responses have been observed in various types of tumours, it is important to note that only a proportion of the tumours that bear p53 mis-sense mutations induce antibodies (Angelopoulou et al, 1994). Thus other biological properties of the tumour and/or the host may allow the production of these responses and these other properties may have clinical significance.

The clinical implications of the development of serum anti-p53 antibodies in cancer patients has been controversial. Most studies show that the presence of such antibodies predicted a poor outcome. In breast cancer, patients who developed anti-p53 antibodies exhibited a shortened overall survival than those without anti-p53 antibodies, and the presence of anti-p53 antibodies was an independent prognostic factor (Schlichtholz et al, 1992; Peyrat et al, 1995). In head and neck squamous cell carcinomas, the presence of anti-p53 antibodies was significantly associated with increased risks of relapse and death (Bourhis et al, 1996). On the other hand, in the newly diagnosed small-cell lung cancer patients the presence of anti-p53 antibodies was not associated with any clinical characteristics or prognostic markers (Rosenfeld et al, 1997). The clinical and biological relevance of anti-p53 antibodies in gastric cancer have not been previously studied in detail.

Gastric cancer is highly prevalent. It was estimated in 1990 to be the second most frequent cancer in the world (after lung cancer), with about 900 000 new cases diagnosed every year. In

spite of a decreasing incidence, the prognosis for patients diag-
nosed with gastric cancer is dismal (Wu et al, 1997). Gastric
cancer currently ranks as the second most common cause of cancer
death and in some countries, especially those of the Far East such
as China and Japan, it is the leading cause of cancer death. These
factors have prompted the search for novel early diagnostic
markers, improved therapies or prognostic factors that would
enable a more effective treatment regimen to be tailored to specific
groups of patients.

In gastric cancer, the *p53* gene is frequently mutated and *p53*
overexpression is observed in about 50% of tumours (Kakeji et al,
1993; Motojima et al, 1994; Gabbert et al, 1995), and anti-p53
antisera were detected in some of the gastric cancer patients (Wurl
et al, 1997). In this study, we examined a large number of gastric
cancer patients for the presence of humoral antibodies against the
tumour suppressor protein p53 and evaluated the clinical and
biological significance of these antibodies in this disease by corre-
lating their presence with the observed features of the tumour and
clinical outcome.

MATERIALS AND METHODS

Patients and sera

Between February 1988 and August 1996, patients diagnosed with
gastric adenocarcinoma who underwent gastric resection at the
Veterans General Hospital (VGH)-Taipei were enrolled in this
study. Patients with two primary tumours were excluded. A total
of 501 patients were included based on fulfillment of the following
criteria: (a) histologically confirmed disease, (b) available of
preoperative serum, and (c) regular post-surgical follow-up.
Control blood was obtained from forty-six cancer-free individuals
during their physical check-up in the VGH-Taipei. Informed
consent was obtained from each patient. Sera were prepared and
stored at –80°C until use.

p53 Antigens

A pCMV vector expressing human p53 mutant protein with a
single amino acid change at codon 143 from valine to alanine was
kindly provided by Dr Bert Vogelstein (Kern et al, 1992). The
pCMV-p53V143A expression vector was introduced into human
p53-null non-small-cell lung cancer (NSCLC) H1299 cells by
electroporation (Chen et al, 1993). H1299 has a homozygous
5′-intragenic deletion of *p53* gene and produces no p53 mRNA or
protein (Unger et al, 1992; Chen et al, 1993). Forty-eight hours
post-transfection, cells were harvested. Cell lysate was prepared
and used as the source of p53 antigen for immunoblot analysis.

Alternatively, bacterially expressed GST-p53 fusion protein
was prepared for immunoblot analysis. cDNA encoding the full
length p53 protein was in-frame fused to the bacterial glutathione
S-transferase (GST) gene. GST and GST-p53 fusion proteins were
expressed in *Escherichia coli* DH5α cells and affinity-purified as
described (Sang et al, 1994).

Immunoblot analysis

H1299 cell lysate containing overexpressed mutant p53 protein
(V143A) and the affinity-purified GST-p53 fusion protein were
used as p53 antigens for immunoblot analysis to detect the
presence of anti-p53 antibodies in patients' sera (Chen et al, 1993).

H1299 whole cell lysates or purified GST-p53 fusion protein were
separated on 10% sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) using a mini-gel apparatus (Hoefer
Mighty Small II). Proteins were then transferred to nitrocellulose
filters (Schleicher and Schuell) followed by blocking with 5%
non-fat dry milk. After drying, the nitrocellulose filters were cut
into 3-mm strips and each strip was subjected to immunoblotting
with each patient's serum (at 1:200 dilution) as primary and sheep
anti-human Ig horseradish peroxidase (HRP) conjugates (at 1:500
dilution, Amersham, Inc.) as secondary antibodies. A colorimetric
assay was employed to detect the presence of HRP by incubating
the filter strips with phosphate-buffered saline (PBS) containing
3,3′-diaminobenzidine (0.5 mg ml^{-1}) and 0.015% hydrogen
peroxide. Mouse anti-p53 monoclonal antibody α1801 (Ab-2,
Oncogene Science) was included positive control (at final concen-
tration of 1 μg ml^{-1}).

Statistical analysis

The χ^2 test and Student's *t*-test were adopted to evaluate clinico-
pathologic features that may relate to the status of p53 antibody
development and the biological behaviour of the tumour. The
following factors were considered: age, sex, tumour size, location
of tumour, gross appearance (superficial, localized or infiltrative),
nuclear grade, mode and depth of cancer invasion, Lauren's,
Ming's and World Health Organization (WHO) histological classi-
fications, stromal reaction pattern, lymphatic duct invasion,
vascular invasion, lymph node metastasis, liver metastasis and
peritoneal dissemination. To further analyse interactions between
all possible factors, a backward step-wise logistic regression
analysis was performed with anti-p53 antibodies as a dependent
variable. We considered a *P*-value > 0.05 for likeness of fit in the
final regression model. Survival curves were plotted using the
Kaplan–Meier method. Comparisons were made by the general-
ized Wilcoxon and Mantel Cox tests. Multivariate survival
analysis (BMDP P2L) was based on the Cox multiple step-wise
regression model. A *P*-value < 0.05 was considered to be statisti-
cally significant. Computation was carried out using BMDP
statistical software (Dixon, 1988).

RESULTS

Detection of serum anti-p53 antibodies in gastric cancer patients

We evaluated the sera from 501 patients with gastric cancer for
the presence of anti-p53 antibodies. Immunoblot analysis was
performed using the patient sera as primary antibodies against cell
lysates prepared from a p53-null human lung cancer H1299 cell
line transfected with a pCMV vector expressing mutant p53 (with
amino acid change at codon 143 from valine to alanine) and the
same line transfected with the parental plasmid containing no p53
cDNA insert (Kern et al, 1992; Chen et al, 1993). After transfec-
tion with pCMV-p53V143A, H1299 cells expressed a substantial
amount of p53 protein which was readily detected by immunoblot
analyses with mouse anti-p53 monoclonal antibody α1801 (Figure
1). Sera from some of the gastric cancer patients also detected a
band with a migration distance similar to that of p53 protein. The
sera scored as positive were those detecting a 53 kDa signal when
blotted against the lysate prepared from pCMV-p53V143A trans-
fectants but no signal from identically prepared mock-transfected

Figure 1 Gastric cancer patients generate humoral antibodies against tumour suppressor p53. Protein extracts (100 µg per preparative gel) prepared from NSCLC-H1299 cells expressing a mutant p53 protein were analysed on a 10% SDS-PAGE gel for immunoblot analysis. After transblotting, the nitrocellulose filter was cut into strips and each strip was blotted against a single patient's serum (at a 1:200 dilution). Sheep anti-human and sheep anti-mouse Ig HRP conjugates were used as secondary antibodies respectively. The presence of HRP was detected colorimetrically. The far right lane represents a positive control (α1801) and p53 signal was indicated by an arrowhead. Signals with a molecular weight other than 53 kDa were also detected in some patients' sera on a less frequent basis


Figure 2 Gastric cancer patients developed circulating antibodies specific for tumour suppressor p53. Affinity-purified GST and GST-p53 fusion proteins (5 µg protein per lane) were separated by 10% SDS-PAGE and immunodetected with sera from different patients (GC944, GC389 and GC498) (at 1:500 dilution) as well as mouse anti-p53 monoclonal antibody α 1801. HRP-conjugated sheep anti-human or mouse Ig were used as secondary antibodies (at 1:5000 dilution). HRP was detected by enhanced chemoluminescence (Amersham, Inc.). The signal of GST-p53 fusion protein (86 kDa) was indicated by the arrowhead

cells or cells transfected with the parental pCMV vector. To independently confirm that the immune response observed was directed against the tumour suppressor protein p53, immunoblot analysis was carried out using affinity-purified GST-p53 protein as antigen. All of the sera which detected the 53 kDa signal against the H1299 transfectant were shown to recognize the 80 kDa GST-p53 fusion protein but not GST protein itself, suggesting that the immune response was specific for the tumour suppressor p53 protein. Figure 2 shows the immunoblot analysis of GST and GST-p53 fusion proteins with two p53 antibody-positive (from patients GC944 and GC389) and one antibody-negative (GC498) sera. Sera from 61 (12.2%) of the 501 gastric cancer patients yielded a positive signal toward tumour suppressor p53 protein by this assay. In contrast, none of the control sera obtained from 46 cancer-free individuals were shown to contain anti-p53 antibodies, consistent with the extremely low incidence of anti-p53 antibodies in normal individuals in other reports.

These anti-p53 antibodies elicited in gastric cancer patients were able to recognize and form complexes with p53 proteins of both the wild-type and mutant conformations as evidenced by immunoprecipitation of [^{35}S]-methionine-labelled p53 proteins synthesized in vitro using a rabbit reticulocyte lysate system by p53-antibody-positive sera (data not shown).

Correlation between anti-p53 antibodies and clinicopathologic status

The correlation of anti-p53 antibodies to clinical and tumour biological parameters was then analysed. As shown in Table 1, univariate analysis demonstrated that the presence of anti-p53 antibodies is significantly associated with several factors including large tumour size, ill-defined gross appearance, poorly differentiated nuclear grade, increased depth of invasion, lymphatic duct invasion and lymph node metastasis. No correlation was found between the presence of anti-p53 antibodies and the other parameters tested. Logistic regression model ($P = 1.000$ for goodness of fit) revealed that lymph node metastasis ($P = 0.002$) and nuclear

grade ($P = 0.003$) were the factors independently associated with the development of these antibodies (data not shown).

All the 501 patients included in this study received only surgical resection without adjuvant or other types of therapy. The cumulative 5-year survival was 51% in this series. As shown in Figure 3, there was a significantly poorer survival rate for patients with anti-p53 antibodies compared to those without them ($P = 0.0038$). The median survival of p53-antibody-negative patients was more than 60 months while it was 24 months for p53-antibody-positive patients. This was also reflected in the 5-year survival rates of 53% and 31% respectively. Table 2 shows the 5-year survival rates according to each parameter in the 501 patients. Anti-p53 antibodies ($P < 0.0038$), along with other tumour- and host-related factors are associated with decreased survival. These factors include tumour size ($P < 0.0001$), ill-defined gross appearance ($P < 0.0001$), poorly differentiated nuclear grade ($P = 0.0002$), expansive type of invasion and invasion to or through the serosa ($P \leq 0.0001$), higher grade in the three commonly used histopathologic classifications ($P \leq 0.01$), stromal reaction ($P < 0.0001$), lymphatic and haematogenous spread ($P \leq 0.0001$), lymph node metastasis ($P < 0.0001$), liver metastasis ($P < 0.0001$) and peritoneal dissemination ($P < 0.0001$). To identify independent factors that would predict patients' outcome, a multivariate analysis was performed using the Cox regression model. Depth of tumour invasion ($P < 0.0001$), poorly differentiated histology (by WHO classification) ($P = 0.03$), venous invasion ($P = 0.0009$), lymph node metastasis ($P < 0.0001$), liver metastasis ($P < 0.0001$) and peritoneal dissemination ($P = 0.0099$) emerged as independent prognostic parameters.

DISCUSSION

Development of tumour-associated antibodies against dominant and recessive oncogenes has been observed in several other tumour types (Caron de Fromentel et al, 1987; Ben-Mahrez et al, 1990; Sorokine et al, 1991; Winter et al, 1992; Angelopoulou et al, 1994), and in some cases, the presence of anti-p53 antibodies is

Table 1 Correlation between the status of serum anti-p53 antibodies to clinicopathological features of gastric cancer patients

	Negative n = 440 (87.8%)	Positive n = 61 (12.2%)	P-value
Age (year)	66.3 ± 10.5	67.5 ± 9.3	0.3390
Sex			
Men	356	55	
Women	84	6	0.0776
Tumour size (cm, mean ± s.d)	5.7 ± 3.4	7.5 ± 2.9	< 0.0001[c]
Location of tumour			
Upper (C)	64	6	
Middle (M)	143	21	
Lower (A)	233	34	0.6089
Gross appearance			
Superficial	139	7	
Localized	62	12	
Infiltrative	239	42	0.0052[c]
Nuclear grade[a]			
Well-differentiated	19	0	
Moderately differentiated	171	12	
Poorly differentiated	250	49	0.0015[c]
Mode of invasion			
Expansive	229	32	
Intermediate	122	20	
Infiltrative	89	9	0.5205
Depth of invasion[b]			
m, sm	124	7	
pm, ss	73	10	
se, si	243	44	0.0151[c]
Japanese histologic type			
Papillary + Tubular	201	32	
Poorly + Signet + Mucinous	239	29	0.3199
Lauren's classification			
Intestinal type	230	22	
Diffuse type	191	35	
Unclassified	19	4	0.0579
Ming's classification			
Expanding type	152	22	
Infiltrative type	288	39	0.8152
Stromal reaction pattern			
Medullary	154	23	
Intermediate	159	21	
Schirrhous	127	17	0.9171
Lymphatic duct invasion			
Negative	129	7	
Positive	311	54	0.0033[c]
Venous invasion			
Negative	414	55	
Positive	26	6	0.2594
Lymph node metastasis			
Negative	184	10	
Positive	256	51	0.0001[c]
Liver metastasis			
Negative	418	56	
Positive	22	5	0.3568
Peritoneal dissemination			
Negative	397	52	
Positive	43	9	0.2319

[a]Nuclear grade was determined according to nuclear pleomorphism of tumour cells, well differentiated: nuclei with minimal variation in size and shape; moderately differentiated: nuclei with moderate variation in size and shape; poorly differentiated: nuclei with marked variation in size and shape
[b]Depth of invasion. m: mucosa; sm: submucosa; pm: proper muscle; ss: subserosa; se: serosa exposed; si: serosa infiltrated .[c]Statistically significant.

Figure 3 Survival curves for gastric cancer patients with and without serum anti-p53 antibodies

correlated to poor prognosis (Schlichtholz et al, 1992; Peyrat et al, 1995; Bourhis et al, 1996). The present study is the first to study a large number of patients with primary gastric adenocarcinoma and determine the frequency at which they generate circulating antibodies against p53, and to correlate the development of antibodies with relevant clinical and biological parameters. Sixty-one of 501 (12.2%) patients were shown to develop these antibodies at levels sufficient to be detected by the Western blot assay used here. The presence of serum anti-p53 antibodies in patients with gastric adenocarcinoma was associated with tumour- and host-related factors including large tumour size, ill-defined tumour margins, poorly differentiated nuclear grade, depth of invasion, lymphatic duct invasion and lymph node metastasis. Anti-p53 antibodies were associated with a poor patient survival. A logistic regression model revealed that lymph node metastasis ($P = 0.002$) and nuclear grade ($P = 0.003$) were the factors independently associated with the development of these antibodies.

It has been reported that mutation of the *p53* gene occurs in approximately 50% of gastric tumours (Kakeji et al, 1993; Motojima et al, 1994). Our data suggest that approximately 20–30% of gastric cancer patients with tumours bearing *p53* gene mutations develop anti-p53 antibodies. This is consistent with previous observations in patients with other types of cancers that approximately this proportion of patients with mutations develop anti-p53 antibodies (Angelopoulou et al, 1994). Thus, not all of the tumours bearing p53 mis-sense mutations induce anti-p53 antibodies, suggesting factors other than simple overexpression of the p53 protein are involved in eliciting the immune response (Angelopoulou et al, 1994). The fact that 84% (51 of 61) of the p53-antibody-positive patients displayed lymph node metastasis suggests that involvement of lymph nodes has hitherto unrecognized importance in eliciting the immune response against overexpressed p53 protein, and that immunological mechanisms by which the development of anti-p53 antibodies may signify an aggressive subset of tumours with p53 mutations with the propensity to involve lymph nodes.

Gastric carcinoma is a world-wide disease with a dismal prognosis. Although surgical resection offers the only prospect of cure, long-term survival of patients with adenocarcinoma of the stomach remains poor because of invasion of the tumour through the muscular layer (advanced cancer) and early lymphatic spread,

Table 2 Association between 5-year survival rates and clinicopathological features of gastric cancer patients

Parameter	No. of patients (total *n* = 501)	5-year survival (%)	Univariate *P*-value	Multivariate *P*-value
Age				
≤ 65	188	54.8		
≥ 65	313	48.6	0.0952	0.5457
Sex				
Men	411	48.5		
Women	90	62.7	0.1252	0.9472
Tumour size				
< 4 cm	162	83.1		
4–8 cm	235	41.1		
> 8 cm	104	26.6	< 0.0001[c]	0.2951
Location of tumour				
Upper (C)	70	59.9		
Middle (M)	164	53.3		
Lower (A)	267	47.2	0.3454	0.8470
Gross appearance				
Superficial	146	90.3		
Localized	74	64.1		
Infiltrative	281	27.9	< 0.0001[c]	0.0748
Nuclear grade[a]				
Well-differentiated	19	62.2		
Moderately differentiated 183	65.4			
Poorly differentiated	299	42.0	0.0002[c]	0.1382
Mode of invasion				
Expansive	261	38.1		
Intermediate	142	66.3		
Infiltrative	98	67.6	0.0001[c]	0.4905
Depth of invasion[b]				
m, sm	131	95.3		
pm, ss	83	72.0		
se, si	287	25.0	< 0.0001[c]	< 0.0001[c]
Japanese histologic type				
Papillary + Tubular	233	62.3		
Poorly + Signet + Mucinous	268	35.2	0.0001[c]	0.0320[c]
Lauren's classification				
Intestinal type	252	63.5		
Diffuse type	226	38.1		
Unclassified	23	47.1	0.0002[c]	0.3811
Ming's classification				
Expanding type	174	65.5		
Infiltrative type	327	43.6	0.0110[c]	0.1723
Stromal reaction pattern				
Medullary	177	55.1		
Intermediate	180	25.4		
Schirrhous	144	72.0	< 0.0001[c]	0.1443
Lymphatic duct invasion				
Negative	136	85.4		
Positive	365	37.7	< 0.0001[c]	0.7611
Venous invasion				
Negative	469	53.0		
Positive	32	23.0	0.0001[c]	0.0009[c]
Lymph node metastasis				
Negative	194	87.6		
Positive	307	29.1	< 0.0001[c]	< 0.0001[c]
Liver metastasis				
Negative	474	53.3		
Positive	27	0.0	< 0.0001[c]	< 0.0001[c]
Peritoneal dissemination				
Negative	449	56.6		
Positive	52	0.0	< 0.0001[c]	0.0099[c]
p53 antibodies				
Negative	440	53.2		
Positive	61	31.3	0.0038*	0.6396

[a]Nuclear grade was determined according to nuclear pleomorphism of tumour cells, well differentiated: nuclei with minimal variation in size and shape; moderately differentiated: nuclei with moderate variation in size and shape; poorly differentiated: nuclei with marked variation in size and shape. [b]Depth of invasion. m: mucosa; sm: submucosa; pm: proper muscle; ss: subserosa; se: serosa exposed; si: serosa infiltrated. [c]Statistically significant.

possibly resulting in residual microscopic disease and relapse after surgical resection (Wu et al, 1996*b*, 1996*c*). In this study, 74% of the tumours were advanced carcinomas and 61% of the patients had lymph node metastases. Since regional lymph node and recurrent nodal involvement have an adverse effect on survival (Wu et al, 1996*a*), gastric resection as well as removal of metastatic lymph nodes are generally considered when attempting curative resection of adenocarcinomas of the stomach. However, the possibility of increased operative risk through the extension of lymphadenectomy with controversial clinical benefit raises concerns about this procedure. In this study, lymph node metastasis and poorly differentiated nuclear grade are independently associated with these antibodies in multivariate analysis. Kakeji et al have reported that gastric cancer with p53 overexpression is highly proliferative and has a high potential for metastasizing to lymph nodes (Kakeji et al, 1993). If lymph node involvement precedes the development of anti-p53 antibodies, detection of antibodies would not be a useful early cancer marker as has been suggested for lung cancer patients (Lubin et al, 1995). The fact that only 12.2% of gastric cancer patients were sero-positive for p53-antibodies further excludes its global use as an early diagnostic marker for this disease. On the other hand, the identification of patients with perhaps occult lymph node metastasis and thus poor prognosis prior to surgical and histopathological detection of metastasis is in itself a worthwhile goal. In contrast to other preoperative image diagnostics, including endoscopic sonography and computerized tomography, the serological assay of anti-p53 antibodies is non-invasive and easy to perform, and may help to pinpoint the subset of patients who should be subjected to gastrectomy with lymph node dissection, or it could also be used along with other established parameters to identify subsets of patients with poor prognosis who may need post-operative adjuvant therapy.

ACKNOWLEDGEMENTS

REFERENCES

Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS (1994) Prevalence of serum antibodies against the *p53* tumor suppressor gene protein in various cancers. *Int J Cancer* **58**: 480–487

Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R and Kohiyama M (1990) Circulating antibodies against c-*myc* oncogene product in sera of colorectal cancer patients. *Int J Cancer* **46**: 35–38

Bourhis J, Lubin R, Roche B, Koscielny S, Bosq J, Dubois I, Talbot M, Marandas P, Schwaab G, Wibault P, Luboinski B, Eschwege F and Soussi T (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. *J Natl Cancer Inst* **88**: 1228–1233

Caron de Fromentel C, May-Levine F, Mouriesse H, Lemerle J, Chandresekaran K and May P (1987) Presence of circulating antibodies against the cellular protein p53 in a notable proportion of children with B cell lymphoma. *Int J Cancer* **39**: 185–189

Chen J-Y, Funk WD, Wright WE, Shay JW and Minna JD (1993) Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. *Oncogene* **8**: 2159–2166

Crawford L, Pim D and Bulbrook R (1982) Detection of antibodies against the cellular protein p53 in sera from patient with breast cancer. *Int J Cancer* **30**: 403–408

Davidoff A, Humphrey P, Iglehart J and Marks J (1991) Genetic basis for p53 overexpression in human breast cancer. *Proc Natl Acad Sci USA* **88**: 5006–5010

Davidoff AM, Iglehart JD and Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. *Proc Natl Acad Sci USA* **89**: 3439–3442

Dixon WJ (1988) *BMDP Statistical Software Manual*. University of California Press: Berkeley

Gabbert HE, Muller W, Schneiders A, Meier S and Hommel G (1995) The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. *Cancer* **76**: 720–726

Kakeji Y, Korenaga D, Tsujitani S, Baba H, Anai H, Maehara Y and Sugimachi K (1993) Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. *Br J Cancer* **67**: 589–593

Kern S, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B (1992) Oncgenic forms of p53 inhibit p53-regulated gene expression. *Science* **256**: 827–830

Lane D and Benchimol S (1990) p53: oncogene or anti-oncogene? *Genes Dev* **4**: 1–8

Levine A, Momand J and Finlay C (1991) The p53 tumour suppressor gene. *Nature* **351**: 453–455

Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, Caron de Fromental C, Preudhomme C, Fenaux P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B and Soussi T (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface. *Cancer Res* **53**: 5872–5876

Lubin R, Zalcman G, Bouchet L, Tredaniel J, Legros Y, Cazals D, Hirsch A and Soussi T (1995) Serum p53 antibodies as early markers of lung cancer. *Nat Med* **1**: 701–702

Motojima K, Furui J, Kohara N, Ito T and Kanematsu T (1994) Expression of p53 protein in gastric carcinoma is not independently prognostic. *Surgery* **116**: 890–895

Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J and Soussi T (1995) Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. *Lancet* **345**: 621–623

Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Vinolas N, Rosell R, Tora M, Real FX, Posner JB and Dalmau J (1997) Aerum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. *J Natl Cancer Inst* **89**: 381–385

Sang BC, Chen J-Y, Minna JD and Barbosa MS (1994) Distinct regions of p53 have a differential role in transcriptional activation and repression functions. *Oncogene* **9**: 853–859

Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F and Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. *Cancer Res* **52**: 6380–6384

Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F and Kohiyama M (1991) Presence of circulating anti-c-myb oncogene product antibodies in human sera. *Int J Cancer* **47**: 665–669

Unger T, Nau M, Segal S and Minna J (1992) p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. *EMBO J* **11**: 1383–1390

Wild CP, Ridanpaa M, Anttila S, Lubin R, Soussi T, Husgafvel-Pursiainen K and and Vainio H (1995) p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumor tissue. *Int J Cancer* **64**: 176–181

Winter SF, Minna JD, Johnson BE, Takahashi T, Gardar AF and Carbone DP (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. *Cancer Res* **52**: 4168–4174

Wu C-W, Hsieh M-C, Lo S-S, Lui W-Y and P'eng F-K (1996a) Results of curative gastrectomy for carcinoma of the distal third of the stomach. *J Am Coll Surg* **183**: 201–207

Wu C-W, Hsieh M-C, Lo S-S, Tsay S-H, Lui W-Y and P'eng F-K (1996b) Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. *Gut* **38**: 525–527

Wu C-W, Hsieh M-C, Lo S-S, Tsay S-H, Lui W-Y and P'eng F-K (1996c) Lymph node metastasis from carcinoma of the distal one-third of the stomach. *Cancer* **73**: 2059–2064

Wu C-W, Hsieh M-J, Lo S-S, Tsay S-H, Li AF-Y, Lui W-Y and P'eng F-K (1997) Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. *Dig Dis Sci* **42**: 1265–1269

Wurl P, Weigmann F, Meye A, Fiittkau M, Rose U, Berger D, Rath F-W, Dralle H and Taubert H (1997) Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. *Scand J Gastroentrol* **32**: 1147–1151